Hologic (NASDAQ:HOLX) Director Christiana Stamoulis Sells 7,402 Shares

Key Points

• Hologic Director Christiana Stamoulis sold 7,402 shares of the company's stock for a total of approximately $540,864, resulting in a 13.52% decrease in their ownership.
• The company's stock has a market capitalization of $16.44 billion and has seen trading activity with a significant volume of over 11 million shares recently, compared to an average of around 2.7 million.
• Analysts have issued various ratings and price targets for Hologic, with an average consensus target price of $79.00, reflecting a predominantly neutral to bullish outlook on the stock.

Hologic, Inc. (NASDAQ:HOLX - Get Free Report) Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the completion of the sale, the director owned 47,336 shares of the company's stock, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Hologic Price Performance

HOLX stock traded down $0.05 during mid-day trading on Wednesday, reaching $73.93. The company's stock had a trading volume of 11,159,323 shares, compared to its average volume of 2,748,507. The stock has a market cap of $16.44 billion, a PE ratio of 30.68, a P/E/G ratio of 2.47 and a beta of 0.63. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The company's 50 day moving average is $67.31 and its two-hundred day moving average is $63.69.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. Hologic's quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

HOLX has been the subject of several analyst reports. Stephens reissued an "equal weight" rating and issued a $76.00 price target (down previously from $78.00) on shares of Hologic in a research note on Wednesday. Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and increased their price target for the company from $72.00 to $87.00 in a research note on Wednesday, August 6th. Morgan Stanley increased their price target on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and increased their price target for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Finally, BTIG Research reissued a "neutral" rating on shares of Hologic in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $79.00.

Hedge Funds Weigh In On Hologic

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Capital Investment Counsel Inc raised its stake in Hologic by 2.6% during the 2nd quarter. Capital Investment Counsel Inc now owns 5,814 shares of the medical equipment provider's stock worth $379,000 after acquiring an additional 150 shares in the last quarter. Greenleaf Trust grew its position in Hologic by 5.1% during the 2nd quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider's stock worth $233,000 after purchasing an additional 173 shares during the last quarter. Farther Finance Advisors LLC grew its position in Hologic by 6.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,712 shares of the medical equipment provider's stock worth $183,000 after purchasing an additional 174 shares during the last quarter. Beverly Hills Private Wealth LLC boosted its holdings in Hologic by 3.6% during the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock worth $320,000 after buying an additional 180 shares in the last quarter. Finally, Great Diamond Partners LLC boosted its holdings in Hologic by 3.4% during the third quarter. Great Diamond Partners LLC now owns 6,098 shares of the medical equipment provider's stock worth $412,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.